Chimeric antigen receptor (CAR) T-cell therapy has shown significant success in treating diffuse large B-cell lymphoma (DLBCL). The initial step involves collecting autologous CD3 lymphocytes through apheresis, in which obtaining an adequate CD3 cell...
BACKGROUND: Chimeric antigen receptor (CAR) T cells targeting CD19 achieve remarkable remissions in refractory B cell malignancies, yet deleterious side effects such as cytokine release syndrome (CRS) limit their broader application. Current preclini...
Biochemical and biophysical research communications
Aug 6, 2025
Chimeric antigen receptor T (CAR-T)-cell therapy has emerged as a promising treatment for hematologic malignancies. Accurate monitoring of CAR expression levels is essential for optimizing therapeutic efficacy and ensuring patient safety. Conventiona...
Chimeric antigen receptor (CAR) T cell immunotherapy represents a breakthrough in the treatment of hematological malignancies, but poor specificity has limited its applicability to solid tumors. By contrast, natural T cells harboring T cell receptors...
International journal of radiation oncology, biology, physics
Apr 3, 2025
PURPOSE: Bridging radiation therapy (BRT) is effective for local control in patients with relapsed or refractory large B cell lymphoma who are undergoing chimeric antigen receptor (CAR) T cell therapy. We hypothesized that adaptive BRT (ABRT), which ...
Clinical lymphoma, myeloma & leukemia
Feb 20, 2025
BACKGROUND: Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment for large B-cell lymphoma (LBCL); however, durable complete responses are achieved in only 30% to 40% of patients. Additionally, CAR-T therapy...
This narrative review examines the promising potential of integrating artificial intelligence (AI) with CRISPR-Cas9 genome editing to advance CAR T-cell therapy. AI algorithms offer unparalleled precision in identifying genetic targets, essential for...
International journal of molecular sciences
Jun 30, 2024
Chimeric antigen receptor (CAR) T cells represent a revolutionary immunotherapy that allows specific tumor recognition by a unique single-chain fragment variable (scFv) derived from monoclonal antibodies (mAbs). scFv selection is consequently a funda...
Reinforcement learning (RL), a subset of machine learning (ML), could optimize and control biomanufacturing processes, such as improved production of therapeutic cells. Here, the process of CAR T-cell activation by antigen-presenting beads and their ...
Cancer poses a formidable challenge in the field of medical science, prompting the exploration of innovative and efficient treatment strategies. One revolutionary breakthrough in cancer therapy is Chimeric Antigen Receptor (CAR) T-cell therapy, an av...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.